All clinical trials being conducted in Metro North should adhere to the GCP principles. Clinical trials comprise not just pharmaceutical trials, but any research investigations involving human participants to test new treatments, interventions or tests. For those clinical trials involving an unapproved drug or device to adhere to GCP guidelines, there is a legal requirement for the trial to be conducted according to GCP. From 1 September 2019, all site Principal Investigators (PIs) of clinical trials being conducted at Metro North must provide evidence of accredited GCP certification undertaken within the previous 3 years. The site PI is then responsible for ensuring respective members of the research team undertake GCP training prior to the commencement of the study. This requirement applies to new studies submitted after September 2019 and does not apply retrospectively to studies that have already been granted SSA authorisation prior to this date.